Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implic...
Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America
About this item
Full title
Author / Creator
Publisher
England: Lupus Foundation of America
Journal title
Language
English
Formats
Publication information
Publisher
England: Lupus Foundation of America
Subjects
More information
Scope and Contents
Contents
The majority of patients with SLE in the USA have been prescribed hydroxychloroquine (HCQ). Given more recent guidelines, the availability of only one strength (200 mg tablets) may limit the flexibility and ability to accurately dose patients with lupus. The Lupus Foundation of America undertook a survey to assess the current landscape of HCQ toler...
Alternative Titles
Full title
Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_37ea5c106a564514a1d12d9c87315c6e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_37ea5c106a564514a1d12d9c87315c6e
Other Identifiers
ISSN
2053-8790
E-ISSN
2053-8790
DOI
10.1136/lupus-2019-000317
